Current Edition

AbbVie

AbbVie, Eli Lilly, Novartis and more cut back in Russia amid corporate exodus over Ukraine war

Since the invasion of Ukraine, hundreds of companies have announced a pause or withdrawal of businesses in Russia. Drugmakers Eli Lilly, Novartis and AbbVie are …

Continue Reading →
diabetes

FDA chides Eli Lilly for second misleading ad in 2 months, this time for diabetes blockbuster Trulicity

After neatly wrapping up concerns over a series of Emgality ads last month, Eli Lilly is back in hot water with the FDA’s Office of …

Continue Reading →
Amgen

For pharmas dealing with HCPs, the future is digital first—and sales reps 2nd

While many people are suffering from Zoom fatigue and looking forward to in-person meetups, that isn’t really the case when it comes to HCPs and …

Continue Reading →
diabetes

Lawmakers blast pharma for ‘outrageous’ prices and ‘anticompetitive conduct’ in culmination of 3-year probe

For years, drugmakers have targeted “weaknesses” in the U.S. healthcare system to reap dividends on older meds, The House Oversight Committee said Friday. The “outrageous …

Continue Reading →
AbbVie

AbbVie’s Rinvoq, Pfizer’s Xeljanz and Lilly’s Olumiant slapped with new FDA warnings amid JAK safety crackdown

The second regulatory shoe has finally dropped for AbbVie, Pfizer and Eli Lilly amid the safety review of JAK inhibitors for inflammatory diseases. But confirmed …

Continue Reading →
antibodies

GlaxoSmithKline and Vir’s sotrovimab stands up to omicron despite other COVID antibodies falling short

Amid reports that COVID-19 antibody treatments from Regeneron and Eli Lilly lose their effectiveness against the omicron variant, GlaxoSmithKline and Vir Biotechnology said on Tuesday …

Continue Reading →
china

Novo Nordisk, Sanofi and Eli Lilly cut insulin prices and lose share in China’s latest cost squeeze

On the centennial of the discovery of insulin, China decided a round of price cuts on the diabetes therapy is due. As a result, foreign …

Continue Reading →
acute heart failure

Eli Lilly and Boehringer Ingelheim’s Jardiance stays on its heart failure winning streak⁠—this time in acute patients

Three months after earning an approval to treat chronic heart failure with their SGLT2 inhibitor Jardiance, Eli Lilly and Boehringer Ingelheim have posted new data …

Continue Reading →
AstraZeneca

J&J’s Invokana chases AZ’s Farxiga and Lilly’s Jardiance with phase 3 heart failure win

Chasing rivals from AstraZeneca and Eli Lilly/Boehringer Ingelheim, Johnson & Johnson’s Invokana is vying for a piece of the lucrative heart failure market. J&J’s Type …

Continue Reading →
Boehringer Ingelheim

Lilly and Boehringer’s Jardiance shows benefits for those with ‘intimately linked’ heart failure and kidney disease

Heart failure and chronic kidney disease often go hand in hand. And when they do, the risk of death and hospitalization increase. A new analysis …

Continue Reading →